Tarriff Talk: Navigating Pharma's Forced Supply Chain Revolution

The pharmaceutical industry faces its most dramatic supply chain restructuring in decades. With U.S. tariffs escalating from 100% to a threatened 250% on branded pharmaceuticals, the economics of global manufacturing have fundamentally shifted overnight. This session examines the structural fault lines reshaping the industry: Can companies afford full reshoring without destroying medicine affordability? How do small pharma compete when only "deep pockets" can self-finance domestic capacity? Why are logistics costs (not just production) now determining competitive advantage? Explore the emerging three-block reality (U.S., Europe+India, China), the hidden trade-offs in nearshoring strategies, and why tariff relief increasingly demands both manufacturing investment and pricing concessions. Discover which supply chain decisions are reversible, and which lock companies into decade-long commitments despite four-year political cycles.